[Translation] A randomized, double-blind, placebo-controlled, multi-center phase IIa clinical study evaluating the preliminary effectiveness, safety, tolerability, pharmacokinetics and pharmacodynamics of 50561 tablets in the treatment of mild to moderate Alzheimer's disease
评价50561片不同用药剂量对比安慰剂治疗轻中度AD患者的初步有效性、安全性和耐受性,并评价50561及其主要代谢产物(如适用)在轻中度AD患者中的PK、PD特征.
[Translation] Evaluate the preliminary efficacy, safety and tolerability of 50561 tablets with different doses compared with placebo in the treatment of mild to moderate AD patients, and evaluate the PK and PD of 50561 and its main metabolites (if applicable) in mild to moderate AD patients feature.